Patient Square Capital LP Acquires New Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Patient Square Capital LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 3rd quarter, Holdings Channel.com reports. The firm bought 90,572 shares of the company’s stock, valued at approximately $2,313,000. Enliven Therapeutics comprises 0.9% of Patient Square Capital LP’s portfolio, making the stock its 9th largest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in ELVN. Quest Partners LLC grew its holdings in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock worth $668,000 after purchasing an additional 2,944 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after purchasing an additional 3,518 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Down 3.4 %

NASDAQ:ELVN opened at $23.61 on Wednesday. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $30.03. The company has a market capitalization of $1.15 billion, a P/E ratio of -12.43 and a beta of 1.02. The firm has a 50-day moving average price of $26.79 and a two-hundred day moving average price of $24.14.

Analyst Ratings Changes

ELVN has been the topic of several recent analyst reports. Robert W. Baird upped their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Insider Buying and Selling

In other news, insider Joseph P. Lyssikatos sold 847 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $25,410.00. Following the completion of the transaction, the insider now owns 1,015,188 shares of the company’s stock, valued at $30,455,640. This represents a 0.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 2,000 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 129,195 shares of company stock worth $3,581,772. 29.20% of the stock is owned by insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.